Uro-oncologic SurgeryMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologicSurgery Builds on existing research collaboration for precision surgery in urology Telix Pharmaceuticals to acquire a 19% stake in Mauna Kea Technologies through a EUR6million equity investment MELBOURNE, Australia & PARIS--(BUSINESS WIRE)--November 13, 2023-- Regulatory News: Telix Pharmaceuticals Limited (ASX: TLX, Telix) and Mauna Kea Technologies (EuronextGrowth: ALMKT, Mauna Kea), today announced an expansion of the IRiS (Imaging and Roboticsin Surgery) Alliance through a strategic EUR6 million investment of Telix in Mauna KeaTechnologies to develop new hybrid pharmaceutical-device products through the combinationof Telix's cancer-targeting agents with Mauna Kea's Cellvizio(R) surgical endomicroscopyplatform. Telix's investment in Mauna Kea will further support the development ofadvanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery,with specific focus on urologic oncology. Telix is a global, commercial-stage biopharmaceutical company focused on thedevelopment and commercialisation of diagnostic and therapeutic radiopharmaceuticals andassociated medical devices. Telix's deep pipeline for prostate, kidney, brain (glioma),hematologic cancers, and rare diseases is underpinned by a reliable and secure globalsupply chain, manufacturing and distribution network. Telix has received globalregulatory approvals from the Australian Therapeutic Goods Administration (TGA), the USFood and Drug Administration (FDA), and Health Canada for its prostate cancer imagingagent, Illuccix(R) , and has more than 20 clinical trials underway worldwide. This strategic investment of Telix in Mauna Kea is highly synergistic with Telix'scurrent diagnostic radiopharmaceutical portfolio as well as with its recent LightpointMedical and Dedicaid GmbH acquisitions. Indeed, when used pre-operatively, Telix's radiopharmaceutical imaging agents such asTLX591-CDx (Illuccix(R) ) or TLX250-CDx potentially enable improved surgical planning todetermine the location and extent of disease. Lightpoint's SENSEI(R) , a radio-guidedsurgical probe works in conjunction with suitable cancer-seeking radiotracer agents toenable the intra-operative detection of cancer during a surgical intervention to helpaccurately answer the question, "where is the cancer?" In a complementary fashion, MaunaKea's Cellvizio platform enables highly localised tissue visualisation throughendomicroscopic fluorescence detection to potentially define and confirm surgical marginsin real-time. Reflecting a shared commitment to building a long-term clinical and commercialpartnership, Telix has agreed to invest 6 million euros to acquire 11 911 852 newordinary shares of Mauna Kea. The new shares are issued by the board of directors ofMauna Kea at a price of 0,5037 euro per share, reflecting a 10% premium over the last10-day VWAP, in a reserved capital increase pursuant to the 21(st) resolution of thecombined shareholders' meeting held on June 2, 2023. Following closing on 17 November2023, Telix will own 19.33% of the share capital and 19.01% of the voting rights of MaunaKea. Dr Christian Behrenbruch, Managing Director and Group CEO of Telix commented: "We arecommitted to expanding this partnership, which brings together the cutting-edgetechnologies in targeted radiation, radio-guided surgery and real-time in vivo cellularimaging our respective companies are developing. This further enhances our differentiatedand innovative offering in urology and continued commitment to engaging with key opinionleaders in the field to deliver significant improvements in surgical techniques andclinical outcomes, in order to improve the lives of the patients we serve." Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, added: "I am verypleased to welcome Telix, a global leader in theranostic radiopharmaceuticals andprecision medicine, as a key Mauna Kea shareholder, another major milestone on ourstrategic partnership roadmap. For many years, Telix and Mauna Kea have shared the visionof linking our two complementary technologies. Our Cellvizio in vivo cellularvisualisation platform is an enabling technology across a range of clinical indicationsthat can use molecular imaging to guide surgical intervention in real-time and it is verycomplementary to Telix's portfolio of late-stage radiopharmaceutical diagnostics,surgical and AI tools, which combined may create a powerful suite of solutions to helpsurgeons perform more precise tumour resections and address some of the most complexissues in uro-oncologic treatment. I am very pleased to see our existing partnershipdeepen and to have the opportunity to advance our shared vision at a moment whenimage-guided surgical technologies are developing rapidly and the need for advancedsolutions has never been greater." In the absence of a public offering, no prospectus will be established in France oroutside of France in connection with Telix's investment in Mauna Kea. About Telix Pharmaceuticals Ltd Telix is a biopharmaceutical company focused on the development and commercializationof diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telixis headquartered in Melbourne, Australia with international operations in the UnitedStates, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio ofclinical-stage products that aims to address significant unmet medical needs in oncologyand rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Formore information, visit www.telixpharma.com About Mauna Kea Technologies
Expand
(20min delay)
